Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Placebo-controlled Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of CYP-002 in Adults with Critical Limb Ischaemia who are Unsuitable for Revascularisation

Next Previous
Trial Profile

A Randomised, Double-blind, Placebo-controlled Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of CYP-002 in Adults with Critical Limb Ischaemia who are Unsuitable for Revascularisation

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYP 002 (Primary)
  • Indications Peripheral ischaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cynata Therapeutics

Most Recent Events

  • 03 Dec 2019 New trial record
  • 25 Nov 2019 According to a Cynata Therapeutics media release, the company expects to start the recruitment of patients early in the coming year.
  • 25 Nov 2019 According to a Cynata Therapeutics media release, The submission of the clinical trial application follows a successful scientific advice meeting that Cynata held with the MHRA earlier this year regarding this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top